https://www.selleckchem.com/pr....oducts/lificiguat-yc
919, 95%CI 0.863-0.979) for renal survival. In terms of adverse events, infection accounted for 56.6%. The incidence of severe infection was 10%, 25% and 50% in PN group, SN-1 group and SN-2 group, respectively. RTX may be a promising option in RNS patients with eGFR ≥ 30ml/min/1.73m . However, it has little effect on prognosis in patients with secondary RNS with eGFR 30ml/min/1.73m , but with a high risk of severe infection. RTX may be a promising option in RNS patients with eGFR ≥ 30 ml/min/1.73m2. However, it has little
Beğen
Yorum Yap
Paylaş
